Navigation Links
Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy
Date:4/9/2014

Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person's own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.

"This clinical trial is to assess ID-G305 and its ability to activate the immune system in patients with advanced stage melanoma, sarcoma, lung, ovarian, or breast cancer," said Amit Mahipal, M.D., M.P.H., medical director of Moffitt's Clinical Research Unit. "Our first patient in this trial is a metastatic sarcoma patient who has undergone two previous surgeries and one chemotherapy regimen."

ID-G305 is a cancer vaccine that is made up of two parts, a protein called NY-ESO-1 that is found in many different types of cancer, and an agent called GLAASTM developed by Immune Design. GLAASTM activates a type of cell called a dendritic cell that normally searches for pathogens in the body and helps the immune system fight against the infection. Following vaccination, the GLAASTM-activated dendritic cells recognize NY-ESO-1 as a foreign protein and cause the body to produce an immune response. Since NY-ESO-1 is found on tumors, the immune system begins targeting the cancer cells.

"Only 10 to 15 percent of all tumors have NY-ESO-1 protein expression. Therefore, patients for this trial need to be to be screened for NY-ESO-1. The vaccine will likely not work for patients with tumors that do not have detectable levels of the protein," said Mahipal.

Each component of ID-G305 has been used previously as a single-agent in clinical trials and was well tolerated by patients. This trial will determine the ideal concentration of each agent to use in combination. Common side effects expected include pain, redness, and inflammation at the site of injection.

This is an exciting time for the development of new immunotherapies to fight cancer. Several immunotherapy agents have recently been approved by the Food and Drug Administration, including interleukin-2 for melanoma and renal cell carcinoma, Provenge for prostate cancer and ipilimumab for melanoma.

"New immune therapies are emerging," explained Mahipal. "If we can have immune therapy actually work it would be great for the patient and reduce side effects associated with traditional chemotherapies."


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt instrumental in FDA approval of revolutionary 2-drug combo to treat advanced melanoma
2. Moffitt Cancer Center launches prostate cancer study focused on black men
3. Single injection may revolutionize melanoma treatment, Moffitt study shows
4. Moffitt researchers identify gene variations that may help predict cancer treatment response
5. Moffitt Cancer Center expert standardizing guidelines for penile cancer treatment
6. Protein complex linked to cancer growth may also help fight tumors, Moffitt researchers say
7. Single men, smokers at higher risk for oral human papillomavirus infection, Moffitt study shows
8. How to boost Hispanics participation in clinical trials? Relate to them, Moffitt study shows
9. New screening approach identifies small proteins unique to melanoma cells, Moffitt researcher says
10. Virus combination effective against deadly brain tumor, Moffitt Cancer Center study shows
11. Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: